A novel tumour marker RCAS1 in a case of extramammary Paget's disease

被引：12

作者：

Enjoji, M

Noguchi, K

Watanabe, H

Yoshida, Y

Kotoh, K

Nakashima, M

Watanabe, T

Nakamuta, M

Nawata, H

机构：

[1] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Higashi Ku, Fukuoka 8128582, Japan

[2] Kyushu Univ, Grad Sch Med Sci, Dept Dermatol, Fukuoka 8128582, Japan

[3] Kyushu Univ, Med Inst Bioregulat, Dept Mol Immunol, Fukuoka 8128582, Japan

来源：

CLINICAL AND EXPERIMENTAL DERMATOLOGY | 2003年 / 28卷 / 02期

关键词：

D O I：

10.1046/j.1365-2230.2003.01251.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

A 66-year-old male, whose primary skin lesion in extramammary Paget's disease had been surgically resected 4 years previously, was hospitalized with liver metastases. Hepatic arterial infusion chemotherapy was carried out and the tumours clearly reduced in size. Serum levels of some common tumour markers were not elevated, even prior to therapy. We measured serum levels of a novel tumour-associated antigen, RCAS1, because its expression was detected in the tumour cells. The patient's serum RCAS1 level was elevated (22.0 U/mL) before therapy and fell during (10.5 U/mL) and after (5.0 U/mL) therapy. Therefore, serum RCAS1 levels may be valuable as a potential biomarker for monitoring therapeutic efficacy against Paget's disease.

引用

页码：211 / 213

页数：3

共 16 条

[1] The tumor-associated antigen, RCAS1, can be expressed in immune-mediated diseases as well as in carcinomas of biliary tract [J].